Interpace Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	41.92	46.93	40.04	31.84	33.12	32.4
Revenue Growth (YoY)	-6.06%	17.21%	25.75%	-3.86%	2.22%	33.77%
Cost of Revenue	15.92	17	14.98	13.61	14.31	21.67
Gross Profit	25.99	29.93	25.06	18.23	18.8	10.73
Selling, General & Admin	20.73	21.14	19.6	20.1	19.88	27.45
Research & Development	0.69	0.68	0.64	0.7	1.49	2.8
Amortization of Goodwill & Intangibles	-	-	0.86	1.27	3.19	4.46
Operating Expenses	21.42	21.82	21.09	22.07	24.57	34.7
Operating Income	4.57	8.11	3.96	-3.84	-5.76	-23.98
Interest Expense	-0.27	-0.66	-1.01	-1.01	-1.04	-0.55
Other Non Operating Income (Expenses)	-0.21	-0.5	-0.67	-1.21	-0.38	0.47
EBT Excluding Unusual Items	4.1	6.95	2.29	-6.06	-7.18	-24.06
Merger & Restructuring Charges	-	-	-	-	-0.9	-2.58
Other Unusual Items	-	-	-0.01	0.22	0.34	0.49
Pretax Income	4.1	6.95	2.28	-5.84	-7.74	-26.15
Income Tax Expense	-0	0	0.02	0.03	-0.71	0.05
Earnings From Continuing Operations	4.1	6.95	2.26	-5.87	-7.04	-26.2
Earnings From Discontinued Operations	-0.3	-0.24	-0.31	-16.09	-7.91	-0.25
Net Income	3.8	6.7	1.95	-21.96	-14.94	-26.45
Preferred Dividends & Other Adjustments	0.46	0.46	-	-	-	3.03
Net Income to Common	3.34	6.24	1.95	-21.96	-14.94	-29.48
Net Income Growth	-44.65%	242.99%	-	-	-	-
Shares Outstanding (Basic)	4	4	4	4	4	4
Shares Outstanding (Diluted)	33	16	4	4	4	4
Shares Change (YoY)	654.43%	260.54%	2.97%	2.49%	2.63%	7.56%
EPS (Basic)	0.75	1.42	0.45	-5.18	-3.61	-7.32
EPS (Diluted)	0.10	0.39	0.45	-5.18	-3.61	-7.32
EPS Growth	-93.60%	-12.13%	-	-	-	-
Free Cash Flow	4.43	3.77	3.32	-8.01	-9.07	-15.55
Free Cash Flow Per Share	0.13	0.24	0.76	-1.89	-2.19	-3.86
Gross Margin	62.01%	63.77%	62.58%	57.26%	56.78%	33.10%
Operating Margin	10.90%	17.28%	9.90%	-12.06%	-17.41%	-74.01%
Profit Margin	7.96%	13.29%	4.88%	-68.97%	-45.12%	-91.01%
Free Cash Flow Margin	10.57%	8.03%	8.29%	-25.17%	-27.40%	-48.01%
EBITDA	4.97	8.41	4.99	-1.28	-0.39	-18.48
EBITDA Margin	11.86%	17.92%	12.46%	-4.02%	-1.18%	-57.03%
D&A For EBITDA	0.4	0.3	1.03	2.56	5.37	5.5
EBIT	4.57	8.11	3.96	-3.84	-5.76	-23.98
EBIT Margin	10.90%	17.28%	9.90%	-12.06%	-17.41%	-74.01%
Effective Tax Rate	-	0.06%	0.74%	-	-	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.